Physician profile
Dana Desantis
NPI 1831740158
$3,504.15
in general payments reported to CMS, 2019-2025
23 companies · $2,102 in 2025
The $2,102 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $209 · 2022: $88.06 · 2023: $130 · 2024: $975 · 2025: $2,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,135 · Education: $72.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,135.06 |
| Education | $72.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $659.58 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $537.09 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $326.76 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $297.03 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $278.76 | 2024-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $244.21 | 2023-2025 | Invega Sustenna |
| Axsome Therapeutics, INC. | $232.43 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $204.03 | 2024-2025 | Cobenfy |
| Novo Nordisk INC | $143.91 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.96 | 2024-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $81.62 | 2025 | Qelbree |
| Neurocrine Biosciences, INC. | $74.51 | 2024-2025 | Ingrezza |
| Pfizer INC. | $67.60 | 2021 | |
| Vanda Pharmaceuticals INC. | $61.97 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $55.74 | 2024-2025 | Trintellix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $20.91 | 2023 | Myrbetriq |
| Idorsia Pharmaceuticals US INC | $19.41 | 2022 | |
| Harmony Biosciences LLC | $18.04 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.04 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.92 | 2023 | Stiolto Respimat |
| Novartis Pharmaceuticals Corporation | $16.48 | 2022 | |
| Glaxosmithkline, LLC. | $16.22 | 2022 | |
| Lilly USA, LLC | $15.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Desantis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.